lanreotide prolonged-release subcutaneous / Generic mfg. - LARVOL DELTA

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study. (PubMed, Eur J Cancer) - P2/3 | "The encouraging results of lanreotide autogel 120 mg as a maintenance treatment after L1 in aggressive G1/2 DP-NET should be confirmed."

Journal • P2 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study. (PubMed, Endocr Relat Cancer) - P3 | "Patients' quality of life did not deteriorate and LAN was well tolerated. Although recruitment stopped early and the predefined sample size was not met, SPINET is the largest prospective study to date of SSA therapy in SSTR positive TCs and ACs and suggests clinical benefit in TCs."

Journal • Metastases • P3 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov) - P3 | N=332 | Active, not recruiting | Sponsor: Camurus AB | Trial completion date: Jul 2028 ➔ Nov 2028 | Trial primary completion date: Jul 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease. (PubMed, Kidney Int) - "Lanreotide did not slow mGFR decline in adults with stage 2/3 ADPKD. The creatinine-eGFR signal is exploratory, not supported by muscle-mass-independent markers, and should be interpreted in the context of a negative primary endpoint. An unexpected hypoglycemia signal warrants proactive monitoring when considering lanreotide in this population."

Clinical • Journal • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Glomerulonephritis • Hypoglycemia • Nephrology • Polycystic Kidney Disease • Renal Disease • CST3

Therapeutic Response and Exploratory Clinicopathological Correlates of Preoperative Lanreotide Autogel in TSH-Secreting Pituitary Tumors (ENDO 2026) - "Preoperative LAN-ATG rapidly improved thyrotoxicosis in TSH-secreting pituitary tumors and induced tumor shrinkage in a subset. In this descriptive series, no clear trend was observed between therapeutic response and number of injections, OST results, or SSTR5 expression, whereas uniformly high SSTR2A expression may support the clinical utility of LAN-ATG."

Clinical • Acromegaly • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • Thyroid Gland Carcinoma • SSTR • SSTR5

MON-030 - Eleven Years of Primary Medical Therapy with Somatostatin Analogs and Pegvisomant in A Young Man with Acromegaly (ENDO 2026) - "He was started on octreotide long-acting release, later switching to lanreotide Autogel at a dose of 120 mg every 4 weeks...Treatment options of surgery, addition of cabergoline, and switch to pasireotide have all been discussed and recommended to avoid complications of GH/IGF-1 excess, but the patient has so far continued to decline these options as he overall feels well... To our knowledge, this is the longest reported case of primary medical therapy in the treatment of acromegaly. While some studies have demonstrated effectiveness of long-term medical therapy for IGF-1 normalization and tumor shrinkage, our patient continues to have markedly elevated IGF-1, placing him at risk for continued complications of acromegaly. Our case underscores the need for individualized treatment approaches and counseling strategies for biochemical control in patients with acromegaly who do not undergo surgery."

Acromegaly • Cardiomyopathy • Endocrine Disorders • Metabolic Disorders • Pituitary Gland Carcinoma • IGF1

Eleven Years of Primary Medical Therapy with Somatostatin Analogs and Pegvisomant in A Young Man with Acromegaly (ENDO 2026) - "He was started on octreotide long-acting release, later switching to lanreotide Autogel at a dose of 120 mg every 4 weeks...Treatment options of surgery, addition of cabergoline, and switch to pasireotide have all been discussed and recommended to avoid complications of GH/IGF-1 excess, but the patient has so far continued to decline these options as he overall feels well... To our knowledge, this is the longest reported case of primary medical therapy in the treatment of acromegaly. While some studies have demonstrated effectiveness of long-term medical therapy for IGF-1 normalization and tumor shrinkage, our patient continues to have markedly elevated IGF-1, placing him at risk for continued complications of acromegaly. Our case underscores the need for individualized treatment approaches and counseling strategies for biochemical control in patients with acromegaly who do not undergo surgery."

Acromegaly • Cardiomyopathy • Endocrine Disorders • Metabolic Disorders • Pituitary Gland Carcinoma • IGF1

ORF28-05 - Effect of CAM2029 on Long-Term Biochemical and Symptom Control in Patients with Acromegaly and IGF-I ≤2×ULN According to Prior Injectable Somatostatin Receptor Ligand Dose: Results from ACROINNOVA 2 (ENDO 2026) - P3 | "Background Many patients with acromegaly do not achieve biochemical control (insulin‑like growth factor I [IGF-I] ≤upper limit of normal [ULN]) or symptom remission with injectable somatostatin receptor ligands (SRLs) such as octreotide long acting repeatable (LAR) and lanreotide Autogel (ATG). Conclusion CAM2029 at a standard dose of 20 mg every 4W improved both biochemical and symptom control in patients with acromegaly who had IGF-I ≤2×ULN on baseline injectable SRLs, regardless of prior SRL dose. These results support CAM2029 as an effective treatment option for acromegaly, including for patients previously escalated to high doses of octreotide LAR or lanreotide ATG."

Clinical • Acromegaly • Endocrine Disorders • IGF1 • SSTR

Lanreotide for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a Korean population: A multicenter prospective observational study (AIM-NETs). (ASCO 2026) - P | "Patients received lanreotide 120 mg deep SC every 4 weeks (dose reduction to 90 mg permitted)... Lanreotide provides robust disease control and a manageable safety profile in Asian patients with advanced GEP-NETs. The observed efficacy, including a favorable ORR, supports lanreotide as a standard of care in this population, aligning with previous clinical trial outcomes."

Clinical • Metastases • Observational data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT (PubMed, Rev Med Inst Mex Seguro Soc) - "Based on the SAGIT instrument, octreotide LAR is more effective for disease control in patients with acromegaly than in those patients treated with lanreotide. The preferential use of octreotide LAR could be recommended in resource-limited settings."

Clinical • Journal • Observational data • Acromegaly • Endocrine Disorders • IGF1

SCALET: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: National Health Research Institutes, Taiwan | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • CTCs

Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches. (PubMed, Drugs) - "Medical therapies in current use for acromegaly are somatostatin receptor ligands (SRLs) (octreotide long-acting release [LAR], octreotide acetate, lanreotide depot, octreotide subcutaneous (SC) depot, pasireotide LAR, oral octreotide, paltusotine), dopamine agonists (cabergoline) and growth hormone receptor antagonists (pegvisomant)...Several investigational drugs are in development towards addressing unmet needs of patients with acromegaly, including new formulations of SRLs (lanreotide prolonged-release formulation, Debio 4126, pasireotide SC depot), novel SRLs (somatoprim, HTL0030310), monoclonal antibodies against growth hormone, and new growth hormone receptor antagonists. Current and emerging therapies are offering renewed hope for disease control. More studies including comparator agents, identification of accurate biomarkers and models predictive of clinical effectiveness may further improve the care of patients with acromegaly."

Journal • Review • Acromegaly • Endocrine Disorders • SSTR

ALXN2420-Acro-201: Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly (clinicaltrialsregister.eu) - P1/2 | N=32 | Suspended | Sponsor: Alexion Pharmaceuticals Inc. | Recruiting ➔ Suspended

Trial suspension • Acromegaly • Endocrine Disorders • IGF1

Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada. (PubMed, Neuroendocrinology) - "Switching between long-acting SSAs can reduce the need for breakthrough medications and lower the incidence of AMRD prescriptions, with a more pronounced effect observed when switching from OCT-LAR to LAN-ATG. These findings have potential implications for improving quality of life and reducing treatment costs for NET patients, which should be evaluated in a formal health economic analysis."

Journal • Observational data • Real-world evidence • Carcinoid Syndrome • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

STRATIFYING BIOCHEMICAL RESPONSE TO SOMATOSTATIN ANALOGS TO GUIDE CARCINOID HEART DISEASE RISK ASSESSMENT (ACC 2026) - " Retrospective analysis was conducted on 53 patients with carcinoid syndrome treated with standard-dose SA (lanreotide 120 mg subcutaneously every 4 weeks or octreotide long-acting release 30 mg intramuscularly every 4 weeks). Biochemical stratification of 5-HIAA response identifies patients at persistent risk for CHD despite SA therapy. Partial responders may benefit from early adjunctive serotonin-lowering therapy, such as telotristat. This approach supports individualized risk-based management, with long-term studies needed to confirm survival benefit."

Carcinoid Syndrome • Cardiovascular • Heart Failure

Somatostatin analogs in advanced typical and atypical pulmonary carcinoids: A multi -center retrospective analysis from Lung NET database (ENETS 2026) - "MATERIALS AND We conducted a retrospective analy - sis of 50 patients with histologically confirmed advanced typical or atypical pulmonary carcinoids treated with SSAs (octreotide LAR or lanreotide autogel) as first-line systemic therapy across four centers. SSA therapy was associated with prolonged disea - se stabilization in most patients with advanced pulmonary car - cinoids. These findings support the continued use of SSAs as a first-line option in this population, while prospective data are nee - ded to better define predictive factors of response."

Metastases • Retrospective data • Carcinoid Syndrome • Endocrine Cancer • Lung Cancer • Neuroendocrine Neoplasm • Solid Tumor

Type 1 gastric NETs: Adjuvant therapy with somatostatin analogues (ENETS 2026) - "All pts received adjuvant therapy with SSA, 62 (80.5%) long-active releasing octreotide30 mg and 15 (19.5%) lanreotide 120 mg eve - ry 4 weeks... Adjuvant therapy with SSA significantly improves relapse-free survival compared to historical controls, demonstra - ting their potential antiproliferative activity in type 1 gastric NETs. However, given the favorable prognosis and low metastasis risk, further prospective studies are needed to define SSA's role in treatment of gNETs type 1, particularly as neoadjuvant therapy for multinodular disease."

Clinical • Gastric Cancer • Gastrointestinal Disorder • Gynaecological Neuroendocrine Tumor • Immunology • Neuroendocrine Tumor • Solid Tumor • GAST

Real-world effectiveness of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs), stratified by Ki-67 proliferation index (Ki-67) and primary tumour location: Post-hoc analyses from KINETICS (ENETS 2026) - "These real-world data support the effectiveness of LAN as a first-line monotherapy in pts with advanced GI- and Pan-NETs, including pts with Ki-67 ≥10%."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

Timing of somatostatin analogue administration and symptom control in neuroendocrine tumors: A real -world analysis integrating clinical and chronobiological parameters (ENETS 2026) - "A retrospective real-world study of 12 patients treated with octreotide LAR or lanreotide autogel (2022–2025) compared CLINICAL SCIENCE - CLINICAL BIOMARKERS49morning (08:00–12:00) and afternoon (13:00–17:00) injections. This real-world observation suggests that the timing and consistency of somatostatin analogue administration may influence symptom stability and biochemical control in NETs. Aligning therapy with circadian rhythms could represent a simple, non-invasive chronotherapeutic strategy deserving validation in larger prospective studies."

Clinical • Real-world • Neuroendocrine Tumor • Oncology • Solid Tumor • CHGA

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: Antonio Fojo | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • SSTR

Efficacy and Safety of Pharmacologic Therapies in Acromegaly: A Systematic Literature Review and Network Meta-Analysis. (PubMed, J Clin Endocrinol Metab) - "This systematic review and NMA consolidate recent high-quality RCT evidence for acromegaly treatments. Paltusotine emerges as a promising alternative to injectable SRLs, with favorable efficacy, safety, and AE-related discontinuation patterns. These findings may inform clinical decision-making and guideline development, if confirmed by clinical experience."

Journal • Retrospective data • Acromegaly • Endocrine Disorders • SSTR

ALXN2420-Acro-201: Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly (clinicaltrialsregister.eu) - P1/2 | N=32 | Recruiting | Sponsor: Alexion Pharmaceuticals Inc.

New P1/2 trial • Acromegaly • Endocrine Disorders • IGF1

Lanreotide acetate subcutaneous injection-induced granulomatous inflammation after surgery for neuroendocrine tumor of unknown primary origin. (PubMed, Int Cancer Conf J) - "The subcutaneous nodule was diagnosed as granulomatous inflammation based on the histopathologic evaluation. Clinicians should be aware that subcutaneous injection of lanreotide acetate may cause granulomatous inflammation, resulting in subcutaneous nodules that may be misdiagnosed as subcutaneous metastases."

Journal • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Clinical effectiveness of everolimus plus somatostatin analogues in advanced neuroendocrine tumors: A retrospective real-world study (ESMO Asia 2025) - "Patients received either everolimus alone or in combination with a somatostatin analogue (lanreotide 120 mg Q4W or octreotide LAR 30 mg Q4W). This real-world study suggests that combining everolimus with a somatostatin analogue may improve PFS over monotherapy in advanced NETs, although statistical significance was not reached. The observed trend aligns with clinical trial data and supports the potential benefit of combination therapy in practice. No significant difference was found between lanreotide and octreotide, indicating both agents may be interchangeable when used with everolimus."

Metastases • Real-world • Real-world evidence • Retrospective data • Neuroendocrine Tumor • Oncology • Solid Tumor

SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov) - P3 | N=332 | Active, not recruiting | Sponsor: Camurus AB | Trial completion date: Dec 2027 ➔ Jul 2028 | Trial primary completion date: Dec 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Neuroendocrine Tumor • Solid Tumor • SSTR